688578 艾力斯
已收盘 04-24 15:00:00
资讯
新帖
简况
每周股票复盘：艾力斯（688578）Q1净利增54.94%
证券之星 · 03:05
每周股票复盘：艾力斯（688578）Q1净利增54.94%
艾力斯(688578.SH)发布一季度业绩，归母净利润6.36亿元，同比增长54.94%
智通财经 · 04-22
艾力斯(688578.SH)发布一季度业绩，归母净利润6.36亿元，同比增长54.94%
艾力斯（688578）披露2026年第一季度报告，4月22日股价上涨2.16%
证券之星 · 04-22
艾力斯（688578）披露2026年第一季度报告，4月22日股价上涨2.16%
3月27日艾力斯涨5.71%，银华中证创新药产业ETF基金重仓该股
证券之星 · 03-27
3月27日艾力斯涨5.71%，银华中证创新药产业ETF基金重仓该股
股市必读：3月13日艾力斯现1笔大宗交易 机构净卖出1521.61万元
证券之星 · 03-16
股市必读：3月13日艾力斯现1笔大宗交易 机构净卖出1521.61万元
每周股票复盘：艾力斯（688578）一周现3笔大宗交易
证券之星 · 03-15
每周股票复盘：艾力斯（688578）一周现3笔大宗交易
3月13日艾力斯现1笔大宗交易 机构净卖出1521.61万元
证券之星 · 03-13
3月13日艾力斯现1笔大宗交易 机构净卖出1521.61万元
3月12日艾力斯现1笔大宗交易 机构净买入948.6万元
证券之星 · 03-12
3月12日艾力斯现1笔大宗交易 机构净买入948.6万元
3月9日艾力斯现1笔大宗交易 机构净买入940.3万元
证券之星 · 03-09
3月9日艾力斯现1笔大宗交易 机构净买入940.3万元
每周股票复盘：艾力斯（688578）预计Q1净利5.9亿元
证券之星 · 03-08
每周股票复盘：艾力斯（688578）预计Q1净利5.9亿元
3月4日艾力斯涨11.17%，银华中证创新药产业ETF基金重仓该股
证券之星 · 03-04
3月4日艾力斯涨11.17%，银华中证创新药产业ETF基金重仓该股
艾力斯：预计2026年1-3月营业收入15.5亿元
证券之星 · 03-03
艾力斯：预计2026年1-3月营业收入15.5亿元
艾力斯(688578.SH)发预增，预计第一季度归母净利润5.9亿元，同比增长43.73%
智通财经 · 03-03
艾力斯(688578.SH)发预增，预计第一季度归母净利润5.9亿元，同比增长43.73%
每周股票复盘：艾力斯（688578）2025年净利增52.55%
证券之星 · 03-01
每周股票复盘：艾力斯（688578）2025年净利增52.55%
艾力斯（688578）披露2025年度业绩快报，2月26日股价下跌1.74%
证券之星 · 02-26
艾力斯（688578）披露2025年度业绩快报，2月26日股价下跌1.74%
艾力斯(688578.SH)2025年度归母净利润21.81亿元，同比增长52.55%
智通财经网 · 02-26
艾力斯(688578.SH)2025年度归母净利润21.81亿元，同比增长52.55%
艾力斯（688578）披露2025年年度业绩预增公告，1月28日股价上涨1.25%
证券之星 · 01-28
艾力斯（688578）披露2025年年度业绩预增公告，1月28日股价上涨1.25%
艾力斯(688578.SH)发预增，预计2025年度归母净利润21.5亿元，同比增加50.37%
智通财经 · 01-28
艾力斯(688578.SH)发预增，预计2025年度归母净利润21.5亿元，同比增加50.37%
艾力斯：目前已有两款产品进入CMC开发阶段
证券日报 · 01-21
艾力斯：目前已有两款产品进入CMC开发阶段
艾力斯：公司自主研发的KRAS G12D选择性抑制剂已于2024年3月获得临床试验默示许可
证券日报 · 01-21
艾力斯：公司自主研发的KRAS G12D选择性抑制剂已于2024年3月获得临床试验默示许可
加载更多
公司概况
公司名称：
上海艾力斯医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2020-12-02
主营业务：
上海艾力斯医药科技股份有限公司的主营业务是肿瘤靶向创新药的研发、生产和营销。公司的主要产品是甲磺酸伏美替尼片、枸橼酸戈来雷塞片、普拉替尼胶囊。
发行价格：
22.73
{"stockData":{"symbol":"688578","market":"SH","secType":"STK","nameCN":"艾力斯","latestPrice":95.32,"timestamp":1777014000000,"preClose":96.37,"halted":0,"volume":5342224,"delay":0,"changeRate":-0.0109,"floatShares":450000000,"shares":450000000,"eps":5.3659,"marketStatus":"已收盘","change":-1.05,"latestTime":"04-24 15:00:00","open":96.52,"high":97.55,"low":94.36,"amount":512000000,"amplitude":0.0331,"askPrice":95.35,"askSize":8,"bidPrice":95.32,"bidSize":0,"shortable":0,"etf":0,"ttmEps":5.3659,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":96.37,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":106.01,"lowLimit":86.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":5.54,"roa":"--","peRate":17.764028,"roe":"8.59%","epsLYR":4.86,"committee":0.124424,"marketValue":42894000000,"turnoverRate":0.0119,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-27。","afterMarket":{"amount":0,"volume":0,"close":95.32,"buyVolume":200,"sellVolume":0,"time":1777016037559,"indexStatus":"已收盘 04-24 15:30:00","preClose":96.37},"floatMarketCap":42894000000},"requestUrl":"/m/hq/s/688578","defaultTab":"news","newsList":[{"id":"2630801098","title":"每周股票复盘：艾力斯（688578）Q1净利增54.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630801098","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630801098?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:05","pubTimestamp":1777143913,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，艾力斯报收于95.32元，较上周的97.58元下跌2.32%。本周，艾力斯4月23日盘中最高价报100.7元。本周关注点来自业绩披露要点：艾力斯2026年一季报显示归母净利润6.36亿元，同比上升54.94%。股本股东变化截至2026年3月31日，艾力斯股东户数为2.03万户，较2025年12月31日增加4586.0户，增幅29.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629472140","title":"艾力斯(688578.SH)发布一季度业绩，归母净利润6.36亿元，同比增长54.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629472140","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629472140?lang=zh_cn&edition=full","pubTime":"2026-04-22 22:13","pubTimestamp":1776867225,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾力斯(688578.SH)披露2026年第一季度报告，报告期公司实现营收15.84亿元，同比增长44.19%;归母净利润6.36亿元，同比增长54.94%;扣非净利润6.33亿元，同比增长59.86%。基本每股收益1.41元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾力斯(688578.SH)发布一季度业绩，归母净利润6.36亿元，同比增长54.94%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629472290","title":"艾力斯（688578）披露2026年第一季度报告，4月22日股价上涨2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629472290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629472290?lang=zh_cn&edition=full","pubTime":"2026-04-22 22:09","pubTimestamp":1776866957,"startTime":"0","endTime":"0","summary":"截至2026年4月22日收盘，艾力斯报收于97.79元，较前一交易日上涨2.16%，最新总市值为440.06亿元。该股当日开盘95.3元，最高98.05元，最低93.8元，成交额达5.01亿元，换手率为1.16%。近日，上海艾力斯医药科技股份有限公司披露《2026年第一季度报告》。总资产8,586,607,887.04元，归属于上市公司股东的所有者权益7,743,802,875.53元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200054283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622493138","title":"3月27日艾力斯涨5.71%，银华中证创新药产业ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622493138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622493138?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:14","pubTimestamp":1774599252,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日艾力斯涨5.71%，收盘报96.8元，换手率1.33%，成交量6.0万手，成交额5.71亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共50家，其中持有数量最多的公募基金为银华基金的银华中证创新药产业ETF。银华中证创新药产业ETF目前规模为124.21亿元，最新净值0.7736，较上一交易日下跌1.02%，近一年上涨8.42%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","688578","06978","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619100708","title":"股市必读：3月13日艾力斯现1笔大宗交易 机构净卖出1521.61万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619100708","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619100708?lang=zh_cn&edition=full","pubTime":"2026-03-16 02:35","pubTimestamp":1773599713,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，艾力斯报收于94.51元，下跌0.37%，换手率0.97%，成交量4.35万手，成交额4.1亿元。当日关注点来自交易信息汇总：3月13日主力资金净流出525.26万元，占总成交额1.28%。大宗交易3月13日艾力斯现1笔大宗交易，机构净卖出1521.61万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600000981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619212077","title":"每周股票复盘：艾力斯（688578）一周现3笔大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2619212077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619212077?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:33","pubTimestamp":1773513189,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，艾力斯报收于94.51元，较上周的97.33元下跌2.9%。本周，艾力斯3月10日盘中最高价报98.5元。3月9日盘中最低价报92.81元。艾力斯当前最新总市值425.3亿元，在化学制药板块市值排名9/150，在两市A股市值排名477/5190。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619985791","title":"3月13日艾力斯现1笔大宗交易 机构净卖出1521.61万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619985791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619985791?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:23","pubTimestamp":1773393815,"startTime":"0","endTime":"0","summary":"证券之星消息，3月13日艾力斯发生大宗交易，交易数据如下：大宗交易成交价格94.51元，成交16.1万股，成交金额1521.61万元，买方营业部为瑞银证券有限责任公司上海花园石桥路证券营业部，卖方营业部为机构专用。近三个月该股共发生3笔大宗交易，合计成交3610.0手。截至2026年3月13日收盘，艾力斯报收于94.51元，下跌0.37%，换手率0.97%，成交量4.35万手，成交额4.1亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300029684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618187131","title":"3月12日艾力斯现1笔大宗交易 机构净买入948.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618187131","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618187131?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:21","pubTimestamp":1773307302,"startTime":"0","endTime":"0","summary":"证券之星消息，3月12日艾力斯发生大宗交易，交易数据如下：大宗交易成交价格94.86元，成交10万股，成交金额948.6万元，买方营业部为机构专用，卖方营业部为摩根大通证券(中国)有限公司上海银城中路证券营业部。近三个月该股共发生3笔大宗交易，合计成交2952.0手。截至2026年3月12日收盘，艾力斯报收于94.86元，下跌1.06%，换手率0.66%，成交量2.99万手，成交额2.85亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200028426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618641722","title":"3月9日艾力斯现1笔大宗交易 机构净买入940.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618641722","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618641722?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:20","pubTimestamp":1773048050,"startTime":"0","endTime":"0","summary":"证券之星消息，3月9日艾力斯发生大宗交易，交易数据如下：大宗交易成交价格94.03元，成交10万股，成交金额940.3万元，买方营业部为机构专用，卖方营业部为摩根大通证券(中国)有限公司上海银城中路证券营业部。近三个月该股共发生2笔大宗交易，合计成交1952.0手。截至2026年3月9日收盘，艾力斯报收于94.03元，下跌3.39%，换手率1.35%，成交量6.06万手，成交额5.7亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900023505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668984","title":"每周股票复盘：艾力斯（688578）预计Q1净利5.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668984","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668984?lang=zh_cn&edition=full","pubTime":"2026-03-08 01:19","pubTimestamp":1772903950,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，艾力斯报收于97.33元，较上周的92.71元上涨4.98%。本周，艾力斯3月4日盘中最高价报101.74元。业绩披露要点艾力斯发布业绩预告，预计2026年1-3月归属净利润盈利约5.9亿元。公司公告汇总上海艾力斯医药科技股份有限公司预计2026年第一季度实现营业收入155,000.00万元，同比增长41.12%；归属于母公司所有者的净利润为59,000.00万元，同比增长43.73%；扣除非经常性损益后的净利润为57,000.00万元，同比增长44.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616899580","title":"3月4日艾力斯涨11.17%，银华中证创新药产业ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616899580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616899580?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:22","pubTimestamp":1772612539,"startTime":"0","endTime":"0","summary":"证券之星消息，3月4日艾力斯涨11.17%，收盘报100.05元，换手率3.12%，成交量14.04万手，成交额13.82亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共50家，其中持有数量最多的公募基金为银华基金的银华中证创新药产业ETF。银华中证创新药产业ETF目前规模为124.21亿元，最新净值0.7781，较上一交易日下跌2.79%，近一年上涨8.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400027757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","688578","BK1574","BK0239","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616346345","title":"艾力斯：预计2026年1-3月营业收入15.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616346345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616346345?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:00","pubTimestamp":1772532025,"startTime":"0","endTime":"0","summary":"证券之星消息，艾力斯发布业绩预告，预计2026年1-3月营业收入15.5亿元。艾力斯2025年三季报显示，前三季度公司主营收入37.33亿元，同比上升47.35%；归母净利润16.16亿元，同比上升52.01%；扣非净利润14.52亿元，同比上升43.62%；其中2025年第三季度，公司单季度主营收入13.59亿元，同比上升42.03%；单季度归母净利润5.65亿元，同比上升38.77%；单季度扣非净利润5.46亿元，同比上升50.2%；负债率10.48%，投资收益1305.31万元，财务费用-3402.25万元，毛利率96.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300032624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616438863","title":"艾力斯(688578.SH)发预增，预计第一季度归母净利润5.9亿元，同比增长43.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616438863","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616438863?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:40","pubTimestamp":1772530817,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾力斯(688578.SH)发布公告，公司预计2026年第一季度实现归属于母公司所有者的净利润为5.9亿元，同比增长43.73%。受益于国家医保政策的支持与覆盖，公司商业化产品销售收入及推广服务收入持续增长，推动公司经营业绩继续攀升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾力斯(688578.SH)发预增，预计第一季度归母净利润5.9亿元，同比增长43.73%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616438628","title":"每周股票复盘：艾力斯（688578）2025年净利增52.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616438628","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616438628?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:44","pubTimestamp":1772300654,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，艾力斯报收于92.71元，较上周的95.68元下跌3.1%。本周，艾力斯2月24日盘中最高价报96.6元。本周关注点来自业绩披露要点：艾力斯2025年归属净利润同比增长52.55%，达21.813亿元。公司公告汇总上海艾力斯医药科技股份有限公司发布2025年度业绩快报，营业总收入为517,170.56万元，同比增长45.36%；归属于母公司所有者的净利润为218,129.29万元，同比增长52.55%。主要原因为核心产品甲磺酸伏美替尼片销售放量，推动收入和利润大幅增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614028513","title":"艾力斯（688578）披露2025年度业绩快报，2月26日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028513","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614028513?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:22","pubTimestamp":1772115738,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，艾力斯报收于92.73元，较前一交易日下跌1.74%，最新总市值为417.28亿元。该股当日开盘94.01元，最高94.49元，最低92.3元，成交额达3.51亿元，换手率为0.84%。近日，上海艾力斯医药科技股份有限公司发布2025年度业绩快报，营业总收入为517,170.56万元，同比增长45.36%；归属于母公司所有者的净利润为218,129.29万元，同比增长52.55%。该数据为初步核算，未经审计，最终以2025年年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614772018","title":"艾力斯(688578.SH)2025年度归母净利润21.81亿元，同比增长52.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614772018","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614772018?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:24","pubTimestamp":1772094280,"startTime":"0","endTime":"0","summary":"艾力斯(688578.SH)披露2025年度业绩快报，2025年度实现营业总收入51.72亿元，同比增长45.36%;归属于母公司所有者的净利润21.81亿元，同比增长52.55%。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606717194","title":"艾力斯（688578）披露2025年年度业绩预增公告，1月28日股价上涨1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717194","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606717194?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:30","pubTimestamp":1769610636,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，艾力斯报收于101.3元，较前一交易日上涨1.25%，最新总市值为455.85亿元。近日，上海艾力斯医药科技股份有限公司发布2025年年度业绩预增公告。公告显示，公司预计2025年度实现营业收入520,000.00万元，同比增长46.15%；归属于母公司所有者的净利润为215,000.00万元，同比增长50.37%；扣除非经常性损益后的净利润为200,000.00万元，同比增长46.95%。上述数据未经注册会计师审计，具体以2025年年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606796565","title":"艾力斯(688578.SH)发预增，预计2025年度归母净利润21.5亿元，同比增加50.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606796565","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606796565?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:36","pubTimestamp":1769589377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾力斯(688578.SH)发布公告，公司预计2025年度实现归属于母公司所有者的净利润为21.5亿元，同比增加50.37%。公司商业化产品聚焦肺癌精准治疗领域，通过差异化的临床治疗优势和专业化的学术推广策略受到业内专家的高度认可。受益于国家医保政策“让新药、好药更加触手可及”的支持与覆盖，公司核心产品销售收入持续增长。此外，公司充分优化资源配置、积极发挥商业化产品间的协同效应，形成多层次的发展动力，推动公司经营业绩持续攀升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605146100","title":"艾力斯：目前已有两款产品进入CMC开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2605146100","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605146100?lang=zh_cn&edition=full","pubTime":"2026-01-21 21:12","pubTimestamp":1769001120,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月21日，艾力斯在互动平台回答投资者提问时表示，公司长期以来致力于小分子创新药物研发，在巩固提升小分子创新药物研发的基础上，近年来公司组建了大分子新药发现团队，搭建了大分子新药研发平台，进一步提升公司研发团队的创新活力。公司大分子团队多个早研项目均在高效有序推进过程中，目前已有两款产品进入CMC开发阶段，希望可以尽快申报IND。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-21/doc-inhiaqzp5288113.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-21/doc-inhiaqzp5288113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BHPRN162.USD","LU0149725797.USD","CMC","LU0170899867.USD","BK0239","LU2237443549.SGD","LU0882574139.USD","688578","LU0971096721.USD","IE00B1BXHZ80.USD","LU2237443465.HKD","LU2746668974.SGD","LU2237443622.USD","LU1363072403.SGD","LU2746668461.USD","LU2237443382.USD","IE00BFXG1179.USD","LU2237443895.HKD","LU0267386448.USD","LU2237443978.SGD","BK4006","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605127100","title":"艾力斯：公司自主研发的KRAS G12D选择性抑制剂已于2024年3月获得临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2605127100","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605127100?lang=zh_cn&edition=full","pubTime":"2026-01-21 21:12","pubTimestamp":1769001120,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月21日，艾力斯在互动平台回答投资者提问时表示，公司自主研发的KRASG12D选择性抑制剂已于2024年3月获得临床试验默示许可；公司从和誉医药引进的新一代EGFR口服小分子抑制剂已于2024年9月获得临床试验默示许可。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-21/doc-inhiaqzp5288254.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-21/doc-inhiaqzp5288254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777162912340,"stockEarnings":[{"period":"1week","weight":-0.0232},{"period":"1month","weight":0.0282},{"period":"3month","weight":-0.0493},{"period":"6month","weight":-0.1096},{"period":"1year","weight":0.0776},{"period":"ytd","weight":-0.0848}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海艾力斯医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20285人(较上一季度增加29.21%)","perCapita":"22183股","listingDate":"2020-12-02","address":"上海市浦东新区周浦镇凌霄花路268号","registeredCapital":"45000万元","survey":" 上海艾力斯医药科技股份有限公司的主营业务是肿瘤靶向创新药的研发、生产和营销。公司的主要产品是甲磺酸伏美替尼片、枸橼酸戈来雷塞片、普拉替尼胶囊。","listedPrice":22.73},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾力斯,688578,艾力斯股票,艾力斯股票老虎,艾力斯股票老虎国际,艾力斯行情,艾力斯股票行情,艾力斯股价,艾力斯股市,艾力斯股票价格,艾力斯股票交易,艾力斯股票购买,艾力斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}